PDCD1 and non-small cell lung carcinoma: Several clinical trials have been initiated, for example, an ongoing phase I/II clinical trial that involves the utilization of HfO2 NPs in combination with SABR and PD-1 inhibitors to treat metastatic NSCLC patients.